

Journal name: Applied Microbiology and Biotechnology

Supplementary Materials

**Substrate Expansion of *Geotrichum candidum* Alcohol Dehydrogenase
towards Diaryl Ketones by Mutation**

Zhongyao Tang¹, Yuuki Takagi¹, Afifa Ayu Koesoema¹, Tomoko Matsuda^{1*}

Department of Life Science and Technology, School of Life Science and Technology, Institute of
Science Tokyo, 4259 Nagatsuta-cho Midori-ku, Yokohama 226-8501, Japan

Corresponding author:

Tomoko Matsuda (tmatsuda@bio.titech.ac.jp, +81-45-924-5757)

Table of contents

1. Synthesis of 13a-17a and 19a by Grignard reaction.....	1
2. Synthesis of <i>rac</i> - 3b-5b and <i>rac</i> - 12b-19b by sodium borohydride reduction.....	1
3. The preparative scale asymmetric reduction of 5a by <i>GcAPRD</i> Phe56Ile.....	3
4. Asymmetric reduction of 12a-19a by <i>GcAPRD</i> Trp288Ala, Phe56Ile/Trp288Ala and Phe56Ala/Trp288Ala	3
Table S1. The primer sequences to prepare <i>GcAPRD</i> Phe56 mutants	5
Table S2. The chiral GC analysis method and retention time of 1a-11a and <i>rac</i> - 1b-11b	5
Table S3. The chiral HPLC analysis method and retention time of <i>rac</i> - 12b-19b	6
Figure S1. SDS-PAGE results of <i>GcAPRD</i> mutants on 12% of polyacrylamide gel	7
Table S4. The ratio of the activity of Phe56Ile to wild type towards 1a-11a	7
Figure S2. Multiple sequences alignment	8
Figure S3. Comparison of the location of the mutation site of <i>GcAPRD</i> with other medium-chain dehydrogenases/reductases (MDRs)	9
References.....	10

1. Synthesis of **13a-17a** and **19a** by Grignard reaction

13a-17a and **19a** were prepared according to a previously reported procedure (Tao et al. 2012). A mixture of 1-bromo-2-methylbenzene (1.664 g, 9.73 mmol) and magnesium (249.6 mg, 10.27 mmol) activated with I₂ (1.0 mg) in dry tetrahydrofuran (THF, 16 mL) was heated at 70°C, then refluxed for 4 h. After cooling to 0°C, a solution of 2-cyanopyridine (852.0 mg, 8.18 mmol) was added dropwise to the mixture. The mixture was warmed to 60°C and stirred overnight. The reaction was quenched with saturated NH₄Cl, and the product was extracted with CH₂Cl₂. The combined organic layer was dried over Na₂SO₄, and the solvent was removed by rotary evaporation under reduced pressure. The residue was then dissolved to Et₂O (64 mL) and 6 N HCl (8 mL) was added to the solution. After stirring at room temperature for 30 min, saturated NaHCO₃ was added until the pH turned to 7. The product was extracted with CH₂Cl₂. The combined organic layer was dried over Na₂SO₄, and the solvent was removed by rotary evaporation under reduced pressure. The product was purified by silica gel column chromatography (hexane: ethyl acetate, 4:1) to give **13a**. **14a-17a** and **19a** were synthesized with the above procedure. The ¹H-NMR spectrum of the products was obtained using 400 MHz Bruker Biospin Avance III 400A spectrometer (Bruker, USA), and compared with the spectra data reported in the literature (Tao et al. 2012; Liu et al. 2019). The results were as follows.

13a (324.3 mg, yield 20%, white solid), ¹H-NMR (400 MHz, CDCl₃): δ=8.68 (d, *J*=4.0 Hz, 1H), 8.07 (d, *J*=7.6 Hz, 1H), 7.87 (t, *J*=7.6 Hz, 1H), 7.45-7.38 (m, 3H), 7.29-7.23 (m, 2H), 2.38 (s, 3H).

14a (348.3 mg, yield 20%, brown oil), ¹H-NMR (400 MHz, CDCl₃): δ=8.72 (d, *J*=4.8 Hz, 1H), 8.01 (d, *J*=7.6 Hz, 1H), 7.89 (td, *J*=7.7 Hz, 1.7 Hz, 1H), 7.84-7.82 (m, 2H), 7.49-7.46 (m, 1H), 7.41-7.35 (m, 2H), 2.42 (s, 3H).

15a (432.9 mg, yield 26%, yellow oil), ¹H-NMR (400 MHz, CDCl₃): δ=8.71 (d, *J*=4.0 Hz, 1H), 8.02-7.97 (m, 3H), 7.90-7.86 (m, 1H), 7.48-7.45 (m, 1H), 7.29-7.27 (m, 2H), 2.42 (s, 3H).

16a (600.2 mg, yield 32%, yellow oil), ¹H-NMR (400 MHz, CDCl₃): δ=8.63 (d, *J*=4.8 Hz, 1H), 8.11 (d, *J*=8.0 Hz, 1H), 7.86 (td, *J*=7.8 Hz, 1.6 Hz, 1H), 7.49 (d, *J*=7.6 Hz, 1H), 7.45-7.33 (m, 4H).

17a (641.6 mg, yield 35%, white solid), ¹H-NMR (400 MHz, CDCl₃): δ=8.73 (d, *J*=4.4 Hz, 1H), 8.09-8.06 (m, 2H), 7.99-7.96 (m, 1H), 7.92 (td, *J*=7.6 Hz, 1.6 Hz, 1H), 7.58-7.55 (m, 1H), 7.53-7.50 (m, 1H), 7.43 (t, *J*=7.8 Hz, 1H).

19a (152.9 mg, yield 9%, white solid), ¹H-NMR (400 MHz, CDCl₃): δ=8.71 (d, *J*=4.4 Hz, 1H), 8.17 (dd, *J*=8.8 Hz, 5.6 Hz, 2H), 8.05 (d, *J*=8.0 Hz, 1H), 7.90 (td, *J*=7.8 Hz, 1.3 Hz, 1H), 7.50-7.47 (m, 1H), 7.15 (t, *J*=8.6 Hz, 2H).

2. Synthesis of *rac*-**3b-5b** and *rac*-**12b-19b** by sodium borohydride reduction

NaBH₄ (129.0 mg, 3.41 mmol) was added to **3a** (580.6 mg, 4.20 mmol) in dry ethanol (20 mL)

and stirred in an ice bath. The suspension was further stirred at room temperature until the reaction was detected completely by TLC. Then the reaction was quenched by the addition of 1N HCl until pH turned to 7-8. After removed ethanol, the residue was extracted with Et₂O, then washed with saturated NaHCO₃. The combined Et₂O layers were dried by MgSO₄ and the solvent was removed by rotary evaporation. The product was purified by silica gel column chromatography (hexane: ethyl acetate, 2:1~4:1) to give *rac*-**3b**. *Rac*-**4b**, *rac*-**5b** and *rac*-**12b-19b** were synthesized with the above procedure. The ¹H-NMR spectrum of the products was obtained using 400 MHz Bruker Biospin Avance III 400A spectrometer (Bruker, USA), and compared with the spectra data reported in the literature (Li et al. 2014; Liu et al. 2019; Nian et al. 2019; Liu et al. 2021). The results were as follows.

rac-**3b** (508.7 mg, yield 77%, colorless oil), ¹H-NMR (400 MHz, CDCl₃): δ=7.33-7.28 (m, 1H), 7.14-7.09 (m, 2H), 6.95 (td, *J*=8.4 Hz, 2.0 Hz, 1H), 4.90 (q, *J*=6.5 Hz, 1H), 1.84 (brs, 1H), 1.49 (d, *J*=6.4 Hz, 3H).

rac-**4b** (652.3 mg, yield 86%, colorless oil), ¹H-NMR (400 MHz, CDCl₃): δ=7.36-7.33 (m, 2H), 7.06-7.00 (m, 2H), 4.90 (q, *J*=6.4 Hz, 1H), 1.77 (brs, 1H), 1.48 (d, *J*=6.4 Hz, 3H).

rac-**5b** (709.1 mg, yield 78%, colorless oil), ¹H-NMR (400 MHz, CDCl₃): δ=7.60 (dd, *J*=7.8 Hz, 1.4 Hz, 1H), 7.34-7.28 (m, 2H), 7.20 (td, *J*=7.6 Hz, 1.6 Hz, 1H), 5.30 (q, *J*=6.4 Hz, 1H), 1.95 (brs, 1H), 1.50 (d, *J*=6.4 Hz, 3H).

rac-**12b** (161.3 mg, yield 84%, white solid), ¹H-NMR (400 MHz, CDCl₃): δ=8.56 (d, *J*=4.8 Hz, 1H), 7.61 (td, *J*=7.6 Hz, 1.6 Hz, 1H), 7.39-7.31 (m, 4H), 7.29-7.24 (m, 1H), 7.18 (dd, *J*=7.2 Hz, 5.2 Hz, 1H), 7.14 (d, *J*=8.0 Hz, 1H), 5.75 (d, *J*=4.0 Hz, 1H), 5.23 (d, *J*=4.4 Hz, 1H).

rac-**13b** (92.5 mg, yield 86%, colorless oil), ¹H-NMR (400 MHz, CDCl₃): δ=8.56 (d, *J*=4.8 Hz, 1H), 7.58 (td, *J*=7.6 Hz, 1.6 Hz, 1H), 7.26-7.24 (m, 1H), 7.19-7.14 (m, 4H), 7.02 (d, *J*=8.0 Hz, 1H), 5.96 (s, 1H), 5.27 (brs, 1H), 2.32 (s, 3H).

rac-**14b** (75.2 mg, yield 66%, white solid), ¹H-NMR (400 MHz, CDCl₃): δ=8.56 (d, *J*=4.8 Hz, 1H), 7.61 (td, *J*=7.8 Hz, 1.6 Hz, 1H), 7.25-7.14 (m, 5H), 7.08 (d, *J*=7.2 Hz, 1H), 5.71 (s, 1H), 5.19 (d, *J*=3.6 Hz, 1H), 2.32 (s, 3H).

rac-**15b** (109.1 mg, yield 90%, white solid), ¹H-NMR (400 MHz, CDCl₃): δ=8.55 (d, *J*=4.8 Hz, 1H), 7.60 (td, *J*=7.7 Hz, 1.7 Hz, 1H), 7.26-7.24 (m, 2H), 7.19-7.13 (m, 4H), 5.72 (d, *J*=3.6 Hz, 1H), 5.15 (d, *J*=4.0 Hz, 1H), 2.32 (s, 3H).

rac-**16b** (85.1 mg, yield 69%, colorless oil), ¹H-NMR (400 MHz, CDCl₃): δ=8.57 (d, *J*=4.8 Hz, 1H), 7.62 (td, *J*=7.7 Hz, 1.7 Hz, 1H), 7.41-7.37 (m, 2H), 7.25-7.18 (m, 4H), 6.27 (d, *J*=3.2 Hz, 1H), 5.43 (d, *J*=4.4 Hz, 1H).

rac-**17b** (94.5 mg, yield 82%, colorless oil), ¹H-NMR (400 MHz, CDCl₃): δ=8.57 (d, *J*=4.8 Hz, 1H), 7.64 (td, *J*=7.7 Hz, 1.7 Hz, 1H), 7.37 (s, 1H), 7.28-7.20 (m, 4H), 7.15 (d, *J*=8.0 Hz, 1H), 5.71 (s, 1H), 5.28 (d, *J*=3.6 Hz, 1H).

rac-18b (215.1 mg, yield >99%, white solid), ¹H-NMR (400 MHz, CDCl₃): δ=8.56 (d, *J*=4.8 Hz, 1H), 7.63 (td, *J*=7.7 Hz, 1.7 Hz, 1H), 7.33-7.28 (m, 4H), 7.22-7.19 (m, 1H), 7.12 (d, *J*=7.6 Hz, 1H), 5.72 (s, 1H), 5.25 (s, 1H).

rac-19b (81.5 mg, yield 78%, white solid), ¹H-NMR (400 MHz, CDCl₃): δ=8.56 (d, *J*=4.8 Hz, 1H), 7.62 (td, *J*=7.7 Hz, 1.7 Hz, 1H), 7.36-7.32 (m, 2H), 7.22-7.19 (m, 1H), 7.12 (d, *J*=8.0 Hz, 1H), 7.03-6.99 (m, 2H), 5.73 (s, 1H), 5.26 (s, 1H).

3. The preparative scale asymmetric reduction of **5a** by GcAPRD Phe56Ile

5a (52.2 mg, 0.34 mmol) was converted to (*S*)-**5b** (41.1 mg, 0.26 mmol, yield 77%, colorless oil), [α]_D²⁰ = -58.4 (c=0.50, CHCl₃, >99% *ee*) (*lit.*(Liang et al. 2018) [α]_D²⁰ = -56.8 (c=1.0, CHCl₃, >99% *ee* (*S*))); ¹H-NMR (400 MHz, CDCl₃): δ=7.59 (dd, *J*=7.8 Hz, 1.4 Hz, 1H), 7.33-7.28 (m, 2H), 7.19 (td, *J*=7.6 Hz, 1.6 Hz, 1H), 5.29 (q, *J*=6.4 Hz, 1H), 1.99 (brs, 1H), 1.49 (d, *J*=6.4 Hz, 3H).

4. Asymmetric reduction of **12a-19a** by GcAPRD Trp288Ala, Phe56Ile/Trp288Ala and Phe56Ala/Trp288Ala

Reduction of **12a**

Trp288Ala: **12a** (6.6 mg, 0.036 mmol, 12 mM) was converted to (*S*)-**12b** (5.1 mg, 0.028 mmol, yield 76%).

Phe56Ile/Trp288Ala: **12a** (6.1 mg, 0.033 mmol, 11 mM) was converted to (*S*)-**12b** (5.7 mg, 0.031 mmol, yield 92%).

Phe56Ala/Trp288Ala: **12a** (6.4 mg, 0.035 mmol, 12 mM) was converted to (*R*)-**12b** (3.5 mg, 0.019 mmol, yield 54%).

¹H-NMR (400 MHz, CDCl₃): δ=8.57 (d, *J*=4.8 Hz, 1H), 7.62 (t, *J*=7.8 Hz, 1H), 7.39-7.27 (m, 5H), 7.21-7.18 (m, 1H), 7.15 (d, *J*=8.0 Hz, 1H), 5.75 (s, 1H), 5.26 (d, *J*=3.6 Hz, 1H).

Reduction of **13a**

Trp288Ala: **13a** (6.2 mg, 0.031 mmol, 11 mM) was converted to (*S*)-**13b** (4.2 mg, 0.021 mmol, yield 67%).

Phe56Ile/Trp288Ala: **13a** (8.0 mg, 0.041 mmol, 14 mM) was converted to (*R*)-**13b** (7.7 mg, 0.039 mmol, yield 95%).

Phe56Ala/Trp288Ala: **13a** (6.0 mg, 0.030 mmol, 10 mM) was converted to (*R*)-**13b** (3.8 mg, 0.019 mmol, yield 63%).

¹H-NMR (400 MHz, CDCl₃): δ=8.60 (d, *J*=4.8 Hz, 1H), 7.60 (td, *J*=7.6 Hz, 1.6 Hz, 1H), 7.24-7.15 (m, 5H), 7.02 (d, *J*=8.0 Hz, 1H), 5.96 (s, 1H), 5.11 (brs, 1H), 2.34 (s, 3H).

Reduction of **14a**

Trp288Ala: **14a** (5.9 mg, 0.030 mmol, 10 mM) was converted to (*R*)-**14b** (4.5 mg, 0.023 mmol,

yield 76%).

Phe56Ile/Trp288Ala: **14a** (8.2 mg, 0.042 mmol, 14 mM) was converted to (*R*)-**14b** (6.6 mg, 0.031 mmol, yield 80%).

Phe56Ala/Trp288Ala: **14a** (6.2 mg, 0.031 mmol, 11 mM) was converted to (*R*)-**14b** (5.2 mg, 0.026 mmol, yield 83%).

¹H-NMR (400 MHz, CDCl₃): δ=8.57 (d, *J*=4.8 Hz, 1H), 7.61 (td, *J*=7.6 Hz, 1.6 Hz, 1H), 7.24-7.14 (m, 5H), 7.09 (d, *J*=7.2 Hz, 1H), 5.71 (s, 1H), 5.22 (brd, *J*=3.2 Hz, 1H), 2.33 (s, 3H).

Reduction of **15a**

Trp288Ala: **15a** (6.3 mg, 0.032 mmol, 11 mM) was converted to (*S*)-**15b** (5.1 mg, 0.026 mmol, yield 80%).

Phe56Ile/Trp288Ala: **15a** (9.0 mg, 0.046 mmol, 15 mM) was converted to (*S*)-**15b** (8.7 mg, 0.044 mmol, yield 96%).

Phe56Ala/Trp288Ala: **15a** (6.8 mg, 0.034 mmol, 12 mM) was converted to (*R*)-**15b** (5.6 mg, 0.028 mmol, yield 82%).

¹H-NMR (400 MHz, CDCl₃): δ=8.56 (d, *J*=4.8 Hz, 1H), 7.61 (td, *J*=7.7 Hz, 1.7 Hz, 1H), 7.26-7.25 (m, 2H), 7.20-7.13 (m, 4H), 5.72 (s, 1H), 5.18 (brd, *J*=2.8 Hz, 1H), 2.32 (s, 3H).

Reduction of **16a**

Trp288Ala: **16a** (6.6 mg, 0.030 mmol, 10 mM) was converted to (*R*)-**16b** (5.6 mg, 0.025 mmol, yield 84%).

Phe56Ile/Trp288Ala: **16a** (10.9 mg, 0.050 mmol, 17 mM) was converted to (*R*)-**16b** (10.5 mg, 0.048 mmol, yield 95%).

Phe56Ala/Trp288Ala: **16a** (6.8 mg, 0.031 mmol, 10 mM) was converted to (*R*)-**16b** (4.9 mg, 0.022 mmol, yield 71%).

¹H-NMR (400 MHz, CDCl₃): δ=8.57 (d, *J*=4.8 Hz, 1H), 7.62 (td, *J*=7.6 Hz, 1.6 Hz, 1H), 7.40-7.37 (m, 2H), 7.25-7.18 (m, 4H), 6.27 (s, 1H), 5.43 (brs, 1H).

Reduction of **17a**

Trp288Ala: **17a** (6.8 mg, 0.031 mmol, 10 mM) was converted to (*R*)-**17b** (5.7 mg, 0.026 mmol, yield 83%).

Phe56Ile/Trp288Ala: **17a** (7.0 mg, 0.032 mmol, 11 mM) was converted to (*R*)-**17b** (6.6 mg, 0.030 mmol, yield 93%).

Phe56Ala/Trp288Ala: **17a** (6.6 mg, 0.030 mmol, 10 mM) was converted to (*R*)-**17b** (2.2 mg, 0.010 mmol, yield 33%).

¹H-NMR (400 MHz, CDCl₃): δ=8.57 (d, *J*=4.8 Hz, 1H), 7.64 (td, *J*=7.7 Hz, 1.7 Hz, 1H), 7.38 (s, 1H), 7.28-7.26 (m, 2H), 7.25-7.20 (m, 2H), 7.15 (d, *J*=7.6 Hz, 1H), 5.71 (d, *J*=3.6 Hz, 1H), 5.27 (brd, *J*=4.0 Hz, 1H).

Reduction of **18a**

Trp288Ala: **18a** (8.3 mg, 0.038 mmol, 13 mM) was converted to (*R*)-**18b** (4.9 mg, 0.022 mmol, yield 56%).

Phe56Ile/Trp288Ala: **18a** (7.3 mg, 0.034 mmol, 11 mM) was converted to (*R*)-**18b** (7.1 mg, 0.032 mmol, yield 96%).

Phe56Ala/Trp288Ala: **18a** (6.7 mg, 0.031 mmol, 10 mM) was converted to (*R*)-**18b** (3.5 mg, 0.016 mmol, yield 51%).

¹H-NMR (400 MHz, CDCl₃): δ =8.57 (d, *J*=4.8 Hz, 1H), 7.63 (t, *J*=7.8 Hz, 1H), 7.33-7.29 (m, 4H), 7.23-7.20 (m, 1H), 7.12 (d, *J*=8.0 Hz, 1H), 5.72 (d, *J*=3.6 Hz, 1H), 5.27 (d, *J*=4.4 Hz, 1H).

Reduction of **19a**

Trp288Ala: **19a** (6.6 mg, 0.033 mmol, 11 mM) was converted to (*R*)-**19b** (4.9 mg, 0.024 mmol, yield 74%).

Phe56Ile/Trp288Ala: **19a** (6.3 mg, 0.031 mmol, 10 mM) was converted to (*R*)-**19b** (5.7 mg, 0.028 mmol, yield 90%).

Phe56Ala/Trp288Ala: **19a** (6.5 mg, 0.032 mmol, 11 mM) was converted to (*R*)-**19b** (5.8 mg, 0.029 mmol, yield 88%).

¹H-NMR (400 MHz, CDCl₃): δ =8.57 (d, *J*=5.2 Hz, 1H), 7.63 (td, *J*=7.7 Hz, 1.7 Hz, 1H), 7.36-7.32 (m, 2H), 7.22-7.19 (m, 1H), 7.11 (d, *J*=7.6 Hz, 1H), 7.05-6.99 (m, 2H), 5.73 (s, 1H), 5.24 (d, *J*=3.2 Hz, 1H).

Table S1. The primer sequences to prepare *GcAPRD* Phe56 mutants

Mutants	Forward primers (5'→3')	Reverse primer (5'→3')
Phe56Ala	<u>GCN</u> CCCATTCCTCCAACAGCGTT	AGAGCCTTGGAGAATGT GCAGGTC
Phe56Val	<u>GTN</u> CCCATTCCTCCAACAGCGTT	
Phe56Ile	<u>ATH</u> CCCATTCCTCCAACAGCGTT	
Phe56His	<u>CAY</u> CCCATTCCTCCAACAGCGTT	

Table S2. The chiral GC analysis method and retention time of **1a-11a** and *rac*-**1b-11b**

Compound	Condition	Retention time (min)			
		Internal standard (3-methyl-1-butanol)	Ketone (a)	Alcohol (b) ^a	
				<i>S</i>	<i>R</i>
1	A	9.1	15.3	19.9	19.6

Table S2. Continued

2	B	6.7	9.0	12.5	12.3
3	B	6.7	9.8	12.9	12.6
4	B	6.7	10.1	12.8	12.5
5	B	6.7	11.9	17.0	16.0
6	B	6.7	12.4	16.8	16.4
7	B	6.7	13.0	17.2	16.6
8	C	6.7	15.3	22.9	22.2
9	D	6.7	13.4	21.8	19.4
10	D	6.7	14.0	20.4	19.7
11	D	6.7	15.0	21.3	20.4

Condition A: 40 °C, 1 min, 5 °C/min, 150 °C, 10 min; Condition B: 40 °C, 1 min, 10 °C/min, 150 °C, 10 min; Condition C: 40 °C, 1 min, 10 °C/min, 160 °C, 15 min; Condition D: 40 °C, 1 min, 10 °C/min, 150 °C, 15 min.

^aThe retention time of *R* and *S* enantiomers was determined by referring to the literature (Koesoema et al. 2019a; Koesoema et al. 2020).

Table S3. The chiral HPLC analysis method and retention time of *rac*-**12b**-**19b**

Compound	Retention time (min) ^a	
	<i>S</i>	<i>R</i>
12b	20.2	23.6
13b	17.2	19.5
14b	18.1	22.0
15b	20.0	22.7
16b	17.5	18.4
17b	18.7	22.6
18b	20.8	25.9
19b	20.5	24.4

HPLC condition: hexane: 2-propanol=9:1, 0.5 mL/min, 254 nm, room temperature.

^aThe retention time of *R* and *S* enantiomers was determined by referring to the literature (Liu et al. 2019; Nian et al. 2019).




Figure S1. SDS-PAGE results of *GcAPRD* mutants on 12% of polyacrylamide gel (Lane M, molecular weight standards; Lane 1, cell-free extract of Phe56Ala; Lane 2, purified Phe56Ala; Lane 3, cell-free extract of Phe56Val; Lane 4, purified Phe56Val; Lane 5, purified Phe56Ile; Lane 6, cell-free extract of Phe56Ile; Lane 7, cell-free extract of Phe56His; Lane 8, purified Phe56His; Lane 9, cell-free extract of Phe56Ile/Trp288Ala; Lane 10, purified Phe56Ile/Trp288Ala; Lane 11, cell-free extract of Phe56Ala/Trp288Ala; Lane 12, purified Phe56Ala/Trp288Ala.)

Table S4. The ratio^a of the activity of Phe56Ile to wild type towards **1a-11a**

Substituent	2'-substituted	3'-substituted	4'-substituted	3', 4' -disubstituted
H	1a 2.2			
F	2a 3.3	3a 3.3	4a 4.8	-
Cl	5a 6.5	6a 5.6	7a 4.2	8a 1.5
Br	9a 4.5	10a 1.1	11a 1.9	-

^aThe ratio was calculated using the relative activity in Fig. 2 and the specific activity in Table 1.

Ratio = (Relative activity of Phe56Ile / Relative activity of wild type) × (48.8 μmol/min/mg / 22.2 μmol/min/mg)



Figure S2. Multiple sequences alignment (Alcohol dehydrogenase from *Thermoanaerobacter brockii* (TbSADH, PDB ID: 1YKF) (Korkhin et al. 1998)^a; *Lactococcus lactis* alcohol dehydrogenase (LlAdhA, PDB ID: 4EEZ) (Liu et al. 2012); alcohol dehydrogenase ADH-A from *Rhodococcus ruber* DSM 44541(ADH-A, PDB ID: 3JV7) (Kroutil and Gruber 2010); acetophenone reductase from *Geotrichum candidum* NBRC 4597 (GcAPRD, PDB ID: 6ISV) (Koesoema et al. 2019b); carbonyl reductase from *Candida parapsilosis* (CPCR2/cpADH5, PDB ID: 4C4O) (Man et al. 2014); Green circle: mutation site of each enzyme.)

^aAlcohol dehydrogenase from *Thermoanaerobacter ethanolicus* (TeSADH) is identical in sequence to TbSADH (Bsharat et al. 2017).




Figure S3. Comparison of the location of the mutation site of *GcARPD* with other medium-chain dehydrogenases/reductases (MDRs)^{a, b}. (A) Crystal structure of binding pockets of *GcARPD* containing the target loop with Phe56; (B) Comparison of *GcARPD* with other MDRs; (C) Spatial alignment result of *GcARPD* and *TeSADH*. (Yellow cavity: small binding pocket in *GcARPD*; blue cavity: large binding pocket in *GcARPD*; peach pink: *GcARPD*; blue: ADH-A; pink: *cpADH5*; yellow: LIAdhA; green: *TbSADH* or *TeSADH*; gray sphere: Zn^{2+} and violet stick: NAD(P)^+ .)

^aThe crystal structure of *GcARPD* was provided from literature (Koesoema et al. 2019b).

^bThe mutation site of other MDRs were provided from the following literatures: *TbSADH* (Ala85Gly/Ile86Leu and Ala85Gly/Ile86Ala/Gln101Ala) (Liu et al. 2019; Qu et al. 2019); ADH-A (Phe43Thr/Tyr54Gly/Leu119Tyr/Phe282Trp) (Maurer et al. 2018); *cpADH5* (Cys57Val/Trp286Ser) (Ensari et al. 2018); LIAdhA (Tyr50Phe/Asn110Ser/Ile212Thr/Leu264Val) (Liu et al. 2012); *TeSADH* (Trp110Ala and Trp110Gly) (Musa et al. 2007; Bsharat et al. 2017).

References

- Bsharat O, Musa MM, Vieille C, Oladepo SA, Takahashi M, Hamdan SM (2017) Asymmetric reduction of substituted 2-tetralones by *Thermoanaerobacter pseudoethanolicus* secondary alcohol dehydrogenase. *ChemCatChem* 9:1487–1493. <https://doi.org/10.1002/cctc.201601618>
- Ensari Y, Dhoke G V, Davari MD, Ruff AJ, Schwaneberg U (2018) A comparative reengineering study of *cpADH5* through iterative and simultaneous multisite saturation mutagenesis. *ChemBioChem* 19:1563–1569. <https://doi.org/10.1002/cbic.201800159>
- Koesoema AA, Standley DM, Ohshima S, Tamura M, Matsuda T (2020) Control of enantioselectivity in the enzymatic reduction of halogenated acetophenone analogs by substituent positions and sizes. *Tetrahedron Lett* 61:151820. <https://doi.org/10.1016/j.tetlet.2020.151820>
- Koesoema AA, Sugiyama Y, T.sriwong K, Xu Z, Verina S, Standley DM, Senda M, Senda T, Matsuda T (2019a) Reversible control of enantioselectivity by the length of ketone substituent in biocatalytic reduction. *Appl Microbiol Biotechnol* 103:9529–9541. <https://doi.org/10.1007/S00253-019-10206-5>
- Koesoema AA, Sugiyama Y, Xu Z, Standley DM, Senda M, Senda T, Matsuda T (2019b) Structural basis for a highly (*S*)-enantioselective reductase towards aliphatic ketones with only one carbon difference between side chain. *Appl Microbiol Biotechnol* 103:9543–9553. <https://doi.org/10.1007/s00253-019-10093-w>
- Korkhin Y, Gilboa AJK, Peretz M, Bogin O, Burstein Y, Frolov F (1998) NADP-dependent bacterial alcohol dehydrogenases: crystal structure, cofactor-binding and cofactor specificity of the ADHs of *Clostridium beijerinckii* and *Thermoanaerobacter brockii*. *J Mol Biol* 278:967–981. <https://doi.org/10.1006/jmbi.1998.1750>
- Kroutil W, Gruber K (2010) Structural insights into substrate specificity and solvent tolerance in alcohol dehydrogenase ADH-‘A’ from *Rhodococcus ruber* DSM 44541. *Chem Commun* 46:6314–6316. <https://doi.org/10.1039/c0cc00929f>
- Li M, Li B, Xia H, Ye D, Wu J, Shi Y (2014) Mesoporous silica KIT-6 supported superparamagnetic CuFe₂O₄ nanoparticles for catalytic asymmetric hydrosilylation of ketones in air. *Green Chem* 16:2680–2688. <https://doi.org/10.1039/c3gc42638f>
- Liang Z, Yang T, Gu G, Dang L, Zhang X (2018) Scope and mechanism on iridium-*f*-amphamide catalyzed asymmetric hydrogenation of ketones. *Chinese J Chem* 36:851–856.

<https://doi.org/10.1002/cjoc.201800129>

Liu B, Qu G, Li J, Fan W, Ma J, Xu Y, Nie Y, Sun Z (2019) Conformational dynamics-guided loop engineering of an alcohol dehydrogenase: Capture, turnover and enantioselective transformation of difficult-to-reduce ketones. *Adv Synth Catal* 361:3182–3190. <https://doi.org/10.1002/adsc.201900249>

Liu J, Li W, Li Y, Liu Y, Ke Z (2021) Selective C-alkylation between alcohols catalyzed by N-heterocyclic carbene molybdenum. *Chem - An Asian J* 16:3124–3128. <https://doi.org/10.1002/asia.202100959>

Liu X, Bastian S, Snow CD, Brustad EM, Saleski TE, Xu J, Meinhold P, Arnold FH (2012) Structure-guided engineering of *Lactococcus lactis* alcohol dehydrogenase LiAdhA for improved conversion of isobutyraldehyde to isobutanol. *J Biotechnol* 164:188–195. <https://doi.org/10.1016/j.jbiotec.2012.08.008>

Man H, Loderer C, Ansorge-schumacher MB, Grogan G (2014) Structure of NADH-dependent carbonyl reductase (CPCR2) from *Candida parapsilosis* provides insight into mutations that improve catalytic properties. *ChemCatChem* 6:1103–1111. <https://doi.org/10.1002/cctc.201300788>

Maurer D, Enugala TR, Hamnevik E, Bauer P, Lüking M, Petrović D, Hillier H, Kamerlin SCL, Dobritzsch D, Widersten M (2018) Stereo- and regioselectivity in catalyzed transformation of a 1,2-disubstituted vicinal diol and the corresponding diketone by wild type and laboratory evolved alcohol dehydrogenases. *ACS Catal* 8:7526–7538. <https://doi.org/10.1021/acscatal.8b01762>

Musa MM, Ziegelmann-Fjeld KI, Vieille C, Zeikus JG, Phillips RS (2007) Asymmetric reduction and oxidation of aromatic ketones and alcohols using W110A secondary alcohol dehydrogenase from *Thermoanaerobacter ethanolicus*. *J Org Chem* 72:30–34. <https://doi.org/https://doi.org/10.1021/jo0616097>

Nian S, Ling F, Chen J, Wang Z, Shen H, Yi X, Yang Y, She Y, Zhong W (2019) Highly enantioselective hydrogenation of non-*ortho*-substituted 2-pyridyl aryl ketones via iridium-*f*-diaphos catalysis. *Org Lett* 21:5392–5396. <https://doi.org/10.1021/acs.orglett.9b01415>

Qu G, Liu B, Jiang Y, Nie Y, Yu H, Sun Z (2019) Laboratory evolution of an alcohol dehydrogenase towards enantioselective reduction of difficult-to-reduce ketones. *Bioresour Bioprocess* 6:18. <https://doi.org/10.1186/s40643-019-0253-9>

Tao X, Li W, Ma X, Li X, Fan W, Xie X, Ayad T, Ratovelomanana-Vidal V, Zhang Z (2012)

Ruthenium-catalyzed enantioselective hydrogenation of aryl-pyridyl ketones. *J Org Chem* 77:612–616. <https://doi.org/10.1021/jo202204j>